JP6250394B2 - 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 - Google Patents

軽度の認知障害（ｍｃｉ）および関連障害の処置方法 Download PDF

Info

Publication number
JP6250394B2
JP6250394B2 JP2013525003A JP2013525003A JP6250394B2 JP 6250394 B2 JP6250394 B2 JP 6250394B2 JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013525003 A JP2013525003 A JP 2013525003A JP 6250394 B2 JP6250394 B2 JP 6250394B2
Authority
JP
Japan
Prior art keywords
disease
administration
compound
app
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013525003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534256A (ja
JP2013534256A5 (https=
Inventor
ヴァーゲス・ジョン
デイル・イー・ブレーデセン
Original Assignee
バック・インスティテュート・フォー・リサーチ・オン・エイジング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バック・インスティテュート・フォー・リサーチ・オン・エイジング filed Critical バック・インスティテュート・フォー・リサーチ・オン・エイジング
Publication of JP2013534256A publication Critical patent/JP2013534256A/ja
Publication of JP2013534256A5 publication Critical patent/JP2013534256A5/ja
Application granted granted Critical
Publication of JP6250394B2 publication Critical patent/JP6250394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013525003A 2010-08-19 2011-08-19 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 Active JP6250394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
US61/401,907 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016160482A Division JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2013534256A JP2013534256A (ja) 2013-09-02
JP2013534256A5 JP2013534256A5 (https=) 2014-10-09
JP6250394B2 true JP6250394B2 (ja) 2017-12-20

Family

ID=45605447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013525003A Active JP6250394B2 (ja) 2010-08-19 2011-08-19 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Country Status (10)

Country Link
US (1) US10449177B2 (https=)
EP (1) EP2605655B1 (https=)
JP (2) JP6250394B2 (https=)
AU (1) AU2011291506B2 (https=)
BR (1) BR112013003847A8 (https=)
CA (1) CA2808630A1 (https=)
DK (1) DK2605655T3 (https=)
ES (1) ES2705027T3 (https=)
MX (1) MX353096B (https=)
WO (1) WO2012024616A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
BR112015002309A2 (pt) 2012-08-07 2017-07-04 Buck Inst Res Aging formulação de múltiplos componentes para aprimorar a função neurológica
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
CA2976258C (en) 2015-02-18 2024-02-20 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
AU2016264228B2 (en) * 2015-05-18 2019-06-13 Synaptec Development Llc Galantamine clearance of amyloidß
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CA3007641C (en) 2015-12-09 2023-10-17 Brandeis University Dbh inhibitors for treating or preventing memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
EP3455223B1 (en) 2016-05-12 2023-11-08 Buck Institute for Research on Aging Compounds to promote normal processing of app
US20210230221A1 (en) 2017-01-03 2021-07-29 Bioatla, Llc Protein therapeutics for treatment of senescent cells
US11026963B2 (en) 2018-07-11 2021-06-08 Rubedo Life Sciences, Inc. Senolytic compositions and uses thereof
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
US12521362B2 (en) 2019-07-25 2026-01-13 Tokyo University Of Science Foundation Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
ES2236682T5 (es) 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
PL205294B1 (pl) 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP4288263B2 (ja) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル， インク． ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
US7794403B2 (en) 2004-04-21 2010-09-14 Mear Holding B.V. System for measuring pulsatile vascular resistance
JP4834837B2 (ja) 2004-04-30 2011-12-14 国立大学法人 千葉大学 精神神経疾患の治療薬
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
EP1844000B1 (en) 2004-12-23 2010-01-27 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
JP2008536866A (ja) 2005-04-15 2008-09-11 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アミン作動性医薬組成物および方法
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2644458A1 (en) 2006-03-01 2007-09-07 Galderma Research & Development Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
US8586627B2 (en) 2007-05-03 2013-11-19 Jack L. Arbiser Honokiol analogs and their use in treating cancers
EP2219449A4 (en) 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
KR101653707B1 (ko) 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
JP5514827B2 (ja) 2008-09-25 2014-06-04 バイオランド リミテッド ４−ｏ−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物
WO2010041279A2 (en) 2008-10-08 2010-04-15 V.B. Medicare Pvt. Ltd. Sustained release drug delivery system
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
EP2432437A4 (en) 2009-05-21 2012-12-19 Bionex Pharmaceuticals Llc TWO- AND ONE-LAYER DOSAGE FORMS
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US20150030683A1 (en) 2012-02-18 2015-01-29 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Also Published As

Publication number Publication date
DK2605655T3 (en) 2019-02-04
AU2011291506A1 (en) 2013-03-14
US20120071468A1 (en) 2012-03-22
AU2011291506B2 (en) 2016-07-28
MX2013001917A (es) 2013-10-25
WO2012024616A1 (en) 2012-02-23
MX353096B (es) 2017-12-19
EP2605655B1 (en) 2018-10-24
JP2013534256A (ja) 2013-09-02
US10449177B2 (en) 2019-10-22
BR112013003847A8 (pt) 2017-12-26
CA2808630A1 (en) 2012-02-23
EP2605655A4 (en) 2014-01-08
ES2705027T3 (es) 2019-03-21
JP2016193944A (ja) 2016-11-17
BR112013003847A2 (pt) 2016-05-31
EP2605655A1 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
JP6250394B2 (ja) 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
US10766867B2 (en) Hydantoins that modulate BACE-mediated APP processing
WO2013123426A1 (en) Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer&#39;s conditions
CN109563089B (zh) 促进app正常加工的化合物
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
US20220041553A1 (en) Apoe4-targeted theraputics that increase sirt1
US20220265605A1 (en) Methods of inducing autophagy using coumarin derivatives and related compounds
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160906

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171122

R150 Certificate of patent or registration of utility model

Ref document number: 6250394

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250